As pharma companies in China face increasing pricing pressure they are looking to innovative business models to boost access and volume, including differential pricing, patient assistance programs and second-brand strategies.
If you are interested in expanding your healthcare company, India is a market full of potential, both for developing biopharmaceuticals and pharmaceuticals, and for manufacturing them. The competitive market, availability of raw materials, and continually growing local market are all factors that contribute to the great opportunities available in India.
In this periodic feature, PharmAsia News Bureau Chief Vikas Dandekar provides his latest analysis on the India pharma industry courtesy of CNBC-TV 18 Mumbai.
In this interview, Vikas decodes one of the biggest mysteries this year to hit the pharma world: Why did Ranbaxy team up with Teva on generic Lipitor (atorvastatin), and what are the terms of that relationship?
The pharmaceutical and life sciences landscape is changing fast in China. There are close to 1,000 bio-related companies in China, and half were established in the last five years or so. Citi expects China’s pharmaceutical market to grow from its current level of $40 billion to $100 billion by 2015 and to $200 billion by 2020, which will make it the second largest in the world, passing Japan along the way.
NEW DELHI - As part of a comprehensive overhaul, India's Department of Ayush, which deals with the Indian traditional system of medicine, locally known as ayurveda, has decided to close 180 ayurveda-based medical colleges that have not been operating according to prescribed standards.